Skip to main content Skip to main navigation menu Skip to site footer

Profil penggunaan antibiotik pada pasien pneumonia di komunitas: tinjauan pustaka

Abstract

Background: Community pneumonia referred to as community acquired pneumonia is pneumonia that is often found in the community and the leading cause of death for infectious diseases. This pneumonia requires therapy with antibiotics. One of the main problems in using antibiotics is the occurrence of antibiotic resistance. This study aims to determine the profile of antibiotic use in patients with community acquired pneumonia, which is commonly referred as acquired pneumonia in the community.

Methods: This study is a literature review that uses articles with a randomized controlled trial design and articles in Indonesian or English and has a publication year, namely the last 10 years. The keywords used were "Treatment" AND "Community acquaired pneumonia" AND "Antibiotic or Antimicrobial" AND "Mortality OR Clinical response OR Severity".

Results: The quality of journals in this study was assessed by means of a critical appraisal skills program checklist and journal reputation. The results obtained were 9 articles that met the inclusion and exclusion criteria. The antibiotic that is often used in outpatient community acquired pneumonia without comorbidities is nemonoxacin 500 mg and in non-severe hospitalized patients the commonly used antibiotic is beta-lactam monotherapy.

Conclusion: The conclusion in this study is that the antibiotic that is often used in outpatient CAP patients is Nemonoxacin 500 mg while inpatient CAP is beta-lactam monotherapy so that in both groups the use of antibiotics is not in accordance with the 2019 ATS guidelines therefore requires monitoring the use of antibiotics in patients with community acquired pneumonia.

 

Latar belakang: Pneumonia komunitas atau biasanya disebut dengan community acquired pneumonia yaitu pneumonia yang sering didapatkan di masyarakat dan merupakan penyebab kematian penyakit menular tertinggi. Pneumonia ini membutuhkan terapi dengan menggunakan antibiotik. Salah satu masalah utama dalam penggunaan antibiotik adalah terjadinya resistensi antibiotik. Penelitian ini bertujuan untuk mengetahui profil penggunaan antibiotik pada pasien community acquired pneumonia atau biasanya disebut dengan pneumonia yang didapatkan di komunitas.

Metode : Penelitian ini merupakan kajian literatur yang menggunakan artikel dengan desain randomized controlled trial dan artikel yang menggunakan bahasa Indonesia atau bahasa inggris dan memiliki tahun publikasi yaitu 10 tahun terakhir. Kata kunci yang digunakan adalah "Treatment" AND "Community acquaired pneumonia" AND “Antibiotic or Antimicrobial” AND “Mortality or Clinical response or Severity”.

Hasil : Kualitas jurnal pada penelitian ini dinilai dengan checklist critical appraisal skill program dan  reputasi jurnal. Hasil yang didapatkan adalah 9 artikel yang memenuhi kriteria inklusi dan ekslusi. Antibiotik yang sering digunakan pada pasien community acquired pneumonia rawat jalan tanpa komorbiditas adalah nemonoxacin 500 mg dan pada pasien rawat inap non severe antibiotik yang sering digunakan adalah monoterapi beta-laktam

Kesimpulan : pada penelitian ini adalah Antibiotik yang sering digunakan pada pasien CAP rawat jalan adalah Nemonoxacin 500 mg sedangkan pada  CAP  rawat inap  adalah monoterapi beta-laktam sehingga pada kedua kelompok tersebut penggunaan antibiotik tidak sesuai dengan guideline ATS tahun 2019 sehingga masih membutuhkan pengawan penggunaan antibiotik pada pasien community acquired pneumonia.

References

  1. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, et al. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25.
  2. Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. Prim Care. 2018;45(3):485-503.
  3. Dunn L. Pneumonia: classification, diagnosis and nursing management. Nurs Stand. 2005;19(42):50-54.
  4. McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Health. 2019;7(1):e47-e57.
  5. Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. J Int Med Res. 2018;46(11):4596-4604.
  6. Utami ER. Antibiotika, Resistensi, dan Rasionalitas Terapi. El-Hayah: Jurnal Biologi. 2011;1(4):191–198.
  7. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-318.
  8. Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global geographic trends in antimicrobial resistance: the role of international travel. J Travel Med. 2019;26(8):taz036.
  9. Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016;16(4):421-430.
  10. Cheng SL, Wu RG, Chuang YC, Perng WC, Tsao SM, Chang YT, et al. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia. J Microbiol Immunol Infect. 2019;52(5):743-751.
  11. Llor C, Pérez A, Carandell E, García-Sangenís A, Rezola J, Llorente M, et al. Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial. Aten Primaria. 2019;51(1):32-39.
  12. Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014 Dec;174(12):1894-901.
  13. Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. Clin Drug Investig. 2012;32(9):569-576.
  14. Nicholson SC, Welte T, File TM Jr, Strauss RS, Michiels B, Kaul P, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240-6.
  15. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312-23.
  16. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019;380(6):517-527.
  17. Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24-29.
  18. Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall HP, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med. 2014;14:105.
  19. Yuan J, Mo B, Ma Z, Lv Y, Cheng SL, Yang Y, et al. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect. 2019;52(1):35-44.
  20. Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565-4572.
  21. Telles JP, Cieslinski J, Gasparetto J, Tuon FF. Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis. Expert Rev Anti Infect Ther. 2019;17(7):501-510.
  22. Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24-29.
  23. Esposito S, Garziano M, Rainone V, Trabattoni D, Biasin M, Senatore L, et al. Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J Transl Med. 2015;13:288.

How to Cite

Faradita, N., Yulia, R., & Herawati, F. (2022). Profil penggunaan antibiotik pada pasien pneumonia di komunitas: tinjauan pustaka. Intisari Sains Medis, 13(2), 340–345. https://doi.org/10.15562/ism.v13i2.1312

HTML
0

Total
0

Share

Search Panel